ARTBIO is a clinical-stage radiopharmaceutical company that develops new alpha radioligand therapies (ARTs). ARTBIO's approach uses tumor-specific targets and the best alpha-precursor isotope (Pb212) to develop safe and effective therapeutics.

<p>ARTBIO is a clinical-stage radiopharmaceutical company that develops new alpha radioligand therapies (ARTs). ARTBIO&#39;s approach uses tumor-specific targets and the best alpha-precursor isotope (Pb212) to develop safe and effective therapeutics. ARTBIO is working with SpectronRx to develop a new prostate cancer therapy called AB001.</p>


ARTBIO

Clinical Trial Finance Associate

Radioprotection Officer

ARTBIO Announces Appointment of Nicole Hadas as Chief Legal OfficerARTBIO | January 21, 2025

Thor Medical and ARTBIO sign strategic long-term supply agreement for Thorium-228ARTBIO, Thor Medical | October 29, 2024

We are delighted to announce that ARTBIO has entered into a master supply agreement with Thor Medical ASA. Thor Medical will supply #thorium (Th-228) to ARTBIO for the manufacturing of Pb212 through our proprietary AlphaDirect technology to support the development of our pipeline of novel #Alpha #Radioligand #Therapies. Learn more: https://shorturl.at/l9GXl 

Thor Medical is pioneering methods to recover Th228 from existing material stockpiles rather than manufacturing it by irradiating other materials. We look forward to working closely with them in our Oslo laboratories, not far away from their production site.

#NuclearMedicine #RadioligandTherapy #Radiopharmaceuticals #Biotech #ProstateCancer #ARTs

 Radionuclide generator 

 Women played a leading role in the pandemic-fueled boom in ... 

Research & DevelopmentAnimal TechnicianOslo

ARTBIO Home Page

ARTBIO and Oslo University Hospital Announce Collaboration to Advance the Research and Development of Alpha Radioligand TherapiesARTBIO, Oslo University Hospital | June 5, 2024

Lilly picks new head of diabetes, obesity unit—Chutes & ...

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of CancerARTBIO, FogPharma | May 14, 2024

Excited about alpha radioligand therapies and peptide science? ARTBIO is hiring!

#radioligandtherapy #peptidechemistry #peptides #SAR #drugdevelopment

The ARTBIO team is excited to attend both the Hanson Wade Group’s 6th Annual Targeted Radiopharmaceuticals Summit Europe and the 36th Annual Piper Sandler Healthcare Conference from December 3-5!

At the Targeted Radiopharmaceuticals Summit Europe in Amsterdam, we’ll connect with industry leaders to exchange insights, explore innovative solutions, and contribute to discussions advancing radiopharmaceutical therapies. Our colleagues Vicki Jardine and Daniel Rossetto will share ARTBIO’s vision for Pb212-based #Alpha #Radioligand #Therapies (#ART).

Emanuele Ostuni is looking forward to in-depth discussions on emerging trends, connecting with experts, and gaining fresh strategies at the Piper Sandler Healthcare Conference. We hope to see you there! 

Learn more about our innovative methods and recent partnerships at https://artbio.com/

#RadioligandTherapy #Radiopharmaceuticals #Biotech #NuclearMedicine

Research & DevelopmentResearch Associate II/Senior Research Associate, BiologyCambridge, MA

ARTBIO, Nucleus RadioPharma Enter Manufacturing & Supply Pact - Contract Pharma

Principal Investigator Dr. Kjetil Berner from Oslo University Hospital will be presenting early clinical data on ARTBIO’s lead program, AB001, a PSMA-targeted 212Pb #Alpha #Radioligand #Therapy for metastatic castration resistant prostate cancer (#mCRPC), at the 2024 European Multidisciplinary Congress on Urological Cancers (#EMUC24).
 
The poster presentation highlights data from the Phase 0 imaging study of AB001. Gamma camera imaging following a 212Pb AB001 microdose showed tumor targeting and promising biodistribution. This early clinical research could lead to more treatment options for patients with prostate cancer in the future. View the poster here: https://lnkd.in/et7_p356
 
Be sure to stop by to learn how we are redefining cancer care by developing a new class of #Alpha #Radioligand #Therapies (#ARTs) based on the ideal isotope #Pb212.
 
#RadioligandTherapy #Radiopharmaceuticals #Biotech #NuclearMedicine #Oncology #ProstateCancer

ARTBIO inks exclusive deal with 3BP to grow radioligand pipeline - The Pharma Letter

Nucleus RadioPharma makes Artbio’s radiopharma assets; Minaris manufactures bluebird’s Lyfgenia - Endpoints News

 ARTBIO’s Exclusive Strategic Collaboration with AlphaGen Therapeutics 

SpectronRx, ARTBIO Partner on Alpha Radioligand Therapy - Contract Pharma

 Eckert & Ziegler and ARTBIO Announce Manufacturing and Supply Partnership for Lead-212 Conjugates 

 The Week's 10 Biggest Funding Rounds: X-Energy And ... 

Radiopharma startup Artbio raises $90M in sign of field’s momentum - BioPharma Dive

Thor Medical invitation to capital markets update | Thor Medical ASA - NTB Kommunikasjon

Fierce Biotech Fundraising Tracker '23

 ARTBIO and SpectronRx Enter a Collaboration to Manufacture Key Components of ARTBIO's AlphaDirect™ Technology 

ARTBIO has a new home for bold ideas and breakthrough science. We have relocated our European research labs to Forskningsparken - Oslo Science Park, opening the door to expanded research #collaborations, new academic #partnerships, and advancing cutting-edge, radiation-enabled R&D and #technology development.
 
 
This move marks more than a change in address. We’re building a space designed to inspire scientific excellence in radiopharmaceutical, preclinical biology research and generate technology advancements for novel cancer treatments. Our new lab brings us even closer to leading academic institutions, research partners, and hospital systems, enabling deeper collaboration and faster progress for the patients we serve.

To our new partners, colleagues, and #community: Thank you for being part of this journey. We can’t wait to get started. Read the press release here: https://lnkd.in/dpagWf4e 
 
#nuclearmedicine #biotech #radiopharmaceuticals #RadioligandTherapy #LifeSciences #CancerCare

Cody AS Thor Medical ASA Jasper C. Kurth Oncoinvent ASA Oslo Cancer Cluster Bjørn Erik Reinseth RADFORSK Anders Tuv Ole Kristian Hjelstuen Leif Rune Skymoen The Life Science Cluster Hanne Mette Kristensen Magnus Skoglund Larsen Hans-Peter Daae

 Artbio raises $23M to advance lead-based radioligand therapies for prostate cancer 

J&J’s Margaret Yu named Artbio CMO - The Pharma Letter

 RLS expands by offering radiopharmaceutical contract ... 

Novartis, Lilly drive investor interest in radiopharmaceuticals

 “Survivor 45” exclusive deleted scene flashes back to day 1 of ... 

BIO announces new CEO—Chutes & Ladders

 ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials 

Artbio brings in $90M for radioactive molecules that target cancer - The Business Journals

Norwegian biotech startup nabs $23M seed to develop radiopharmaceuticals for prostate cancer - ArcticStartup - ArcticStartup

SpectronRx, ARTBIO Partner On Alpha Radioligand Therapy - Contract Pharma

ARTBIO Raises Oversubscribed and Upsized $90 Million Series A Financing to Progress Pipeline and Isotope Technology Development for New Class of Alpha Radioligand Therapies - PR Newswire

Artbio emerges with $23M to make radioligand therapies for prostate cancer, with field still in 'early days' - Endpoints News

 FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle ... 

🏃♀️ 𝗖𝗼𝗹𝗹𝗮𝗯𝗼𝗿𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗺𝗼𝘁𝗶𝗼𝗻! 🏃♂️

This past Saturday, NucliThera laced up for 𝗛𝗼𝗹𝗺𝗲𝗻𝗸𝗼𝗹𝗹𝘀𝘁𝗮𝗳𝗲𝘁𝘁𝗲𝗻 - one of the world's largest relay races - joining forces with our colleagues from ARTBIO and Oncoinvent ASA to form a 𝘂𝗻𝗶𝘁𝗲𝗱 𝘁𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗿𝗮𝗱𝗶𝗮𝘁𝗶𝗼𝗻 𝘁𝗵𝗲𝗿𝗮𝗽𝘆 𝘁𝗲𝗮𝗺!

As a small and growing company, collaboration is at the heart of what we do — not just in science, but in spirit. We're proud that Anna Maria Sæther represented NucliThera on the course, embodying the energy and determination we bring to our mission: delivering new and effective treatments to people living with cancer.

This year also celebrates 50 years of female participation in the event — a powerful reminder of the progress that can be made when barriers are broken and inclusion is prioritized.

👏 Huge thanks to everyone who ran, cheered, and made it a day to remember. It was a celebration of science, health, and shared determination — on the track and beyond 💪

🎉 Special thanks to Elisa Napoli, PhD, whose initiative and organization turned this idea into an unforgettable race-day collaboration.

#Holmenkollstafetten #RadioligandTherapy #NucliThera #CancerResearch #WomenInScience #Collaboration

Tanja Aarvak, Elise Damlien, Roxanne Wouters, Kim Lindland, Amaury Guillou, PhD, Nisarg Soni, Ph.D, Wouter van Eijmeren, Ruth Gong Li, Richard Crispin, Célia Seillier, PhD

 ARTBIO: $90 Million Secured To Develop New Class Of Alpha Radioligand Therapies 

www.artbio.com

ARTBIO Launches to Develop New Class of Alpha Radioligand Therapies Designed to Maximize Therapeutic Potential - PR Newswire

Artbio and 3B Pharmaceuticals to advance α-radioligand therapy for solid tumors - BioWorld Online

Deals Report: J&J acquires Proteologix, Fog-ARTbio to develop radiotherapies - BioCentury

Technical Operations & ManufacturingRadioprotection OfficerOslo

Swiss Biotech Day is here! ARTBIO is participating and supporting the Swiss biotech ecosystem with two important contributions by our CEO Emanuele Ostuni:
 
Unleashing the power of Alpha Radioligand Therapy (ART) tomorrow at 12:45
 
Radio Therapy Panel sponsored by Molecular Partners tomorrow at 15.00 - hosted by Philippe Legenne, with  Melpomeni Fani, University Hospital Basel, Sibylle Jennings, Novartis and Arnaud Lesegretain, Orano Med. 

We look forward to the insights and continued progress for the field of #alpha #radioligand #therapy

#nuclearmedicine #radiopharmaceuticals #swissbiotechday

Ivana Galetic Conrad Wüller Swiss Biotech Association

Thor Medical and ARTBIO sign strategic long-term supply agreement for Thorium-228 - NTB Kommunikasjon

 AlphaGen and ArtBio Form China-US Partnership for Radioligand Therapies 

 ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors 

 Oncoinvent Announces Agreement with ARTBIO to Collaborate on Radiopharma Laboratory Facilities 

Please join us in welcoming Amra Demirovic as Chief Human Resources Officer!

Amra brings extensive experience in human resources and a proven track record of fostering inclusive workplace cultures. Amra comes to us from BeiGene, where she led HR for Europe & New Markets. Prior to that, she held key HR positions at Novartis. 

Amra loves sports and exploring the world with her son.

Welcome to the team, Amra! 

#nuclearmedicine #radioligandtherapy #radiopharmaceuticals #biotech #team

Thor Medical and ARTBIO Forge Strategic Supply Partnership - TipRanks

FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer - Business Wire

 Nucleus RadioPharma unveils manufacturing pact with ARTBIO 

 FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer 

ARTBIO, Nucleus RadioPharma Partner to Advance Targeted Alpha Radioligand Therapies for Cancer - HIT Consultant

ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products Containing Radioisotope Pb-212 to Support Emerging Clinical Trials - Business Wire

The group I'm in at ARTBIO is growing! We are looking for a biochemist/biophysicist with some plate based assay experience (SPR or ITC experience are a plus)! Reach out if you're interested or know someone that might be a good fit! 

 https://lnkd.in/ePUZqZVk 

ARTBIO Announces Appointment of Margaret Yu, M.D., as Chief Medical OfficerARTBIO | January 9, 2025

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid TumorsARTBIO, 3B Pharmaceuticals | November 14, 2024

Our very own Victor Paulus was featured in the latest episode of “A Dose of Reality” podcast. It’s talented and driven colleagues like Victor that help build ARTBIO and enable us to bring life-changing and innovative #alpha #radioligand #therapies to patients in need.
 
Check out the episode in the link below to learn why ARTBIO is a special place for Victor, but also to learn from his experiences in regulatory, drug development the exciting space of #radiopharmaceuticals.

Excited to be heading to Bergen soon for this year's LSX Nordic Congress (20-21 May) to (re)connect and exchange with peers, academia and investors. Especially looking forward to our panel discussion on the evolving world of #radiopharmaceuticals.

Oystein Soug Jutta Heix Lars Mørland Knudsen Frans Suurs ARTBIO Oslo Cancer Cluster Oncoinvent ASA p53 Bayer

#nuclearmedicine #radioligandtherapy


              ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors
            

Investors pour $90M onto ARTBIO's palette 6 months after ...

 ARTBIO and Nucleus RadioPharma Announce Collaboration to Manufacture GMP-Grade Therapeutic Products ... 

SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy AB001 for Indiana and Surrounding States - Business Wire

 Artbio raises $90M as radiopharma field finds its footing 

 Updated: Radiopharmaceuticals Market Predicted to Grow ... 

 GSK, Novartis, among winners at LSX Awards - BioProcess ... 

Artbio launches for alpha-emitting radiopharmaceuticals to treat cancer - Chemical & Engineering News

Redefining cancer care is not only about taking the right medication. Early cancer detection is a vital tool in the battle against prostate cancer. That’s why we are proud to support Prostate Cancer Research’s latest #ProactiveForYourProstate campaign. 
 
In the UK and elsewhere, prostate cancer is now one of the most common cancer types. We applaud PCR’s efforts to establish a national screening program in the UK designed to detect prostate cancer early when it’s the most treatable.
 
ARTBIO is proud to be a Proactive Champion supporter. If you’re interested in helping to advance this worthwhile cause, please consider joining PRC’s Campaign Action Network: https://lnkd.in/ezkJSSgk 
 
#prostatecancer #oncology #preventativemedicine #biotech #nuclearmedicine

ARTBIO team members Emanuele Ostuni, Nick Pullen, and Conrad Wüller will attend the J.P. Morgan 43rd Annual Healthcare Conference in San Francisco next month! 

We're eager to connect with industry leaders, share our progress, and explore partnerships to advance #Alpha #Radioligand #Therapies (#ART) as a transformative treatment for #Cancer.

We're also honored to have the opportunity to present our company on Thursday, January 16, at 9:00 AM as part of the conference agenda.

#JPM25 #Radiopharmaceuticals #Biotech #NuclearMedicine


ARTBIO Expands Radiopharmaceutical R&D Capabilities with Move to Oslo Science ParkARTBIO, Oslo Science Park | May 16, 2025

CDMO Nucleus RadioPharma links up with ARTBIO to help produce prostate cancer candidate for clinical trials - FiercePharma

ARTBIO, PharmaLogic Enter Manufacturing And Supply Pact - Contract Pharma

FogPharma, Artbio join forces to design a different radiopharma drug - BioPharma Dive

ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors - PR Newswire

ARTBIO divulges plans for proprietary isotope manufacturing technology - Pharmaceutical Technology

ARTBIO and SpectronRx Enter a Collaboration to Manufacture Key Components of ARTBIO's AlphaDirect™ Technology - PR Newswire

 Fogpharma and Artbio collaborate to create new class of α-radioligand therapeutics for solid tumors 

 Nucleus RadioPharma makes Artbio’s radiopharma assets; Minaris manufactures bluebird’s Lyfgenia 

 ARTBIO Announces Appointment of Nick Pullen, Ph.D., as Chief Scientific Officer 

ARTBIO, PharmaLogic Enter Manufacturing and Supply Pact - Contract Pharma

The ARTBIO team is excited to be attending several upcoming events in the coming weeks, including the William Blair Conference, the ICPO Foundation-International Centers for Precision Oncology Theranostics Summit, and the 2024 Jefferies London Healthcare Conference!

ARTBIO Chief Scientific Officer Nick Pullen will be speaking at the ICPO Summit with a first disclosure of pre-clinical data underwriting the superiority of alpha emission in a bone metastasis Prostate Cancer model, as well as clinical data from a Ph0 evaluation of AB001.

ARTBIO Chief Executive Officer Emanuele Ostuni will be joining Andy Hsieh for a fireside chat as part of the William Blair’s Innovator Series: Radiopharmaceuticals, discussing ARTBIO’s vision for Pb212-based alpha radioligand therapies and the progress the company has made since its inception.

We look forward to insightful discussions and sharing the latest updates about our approach to #Alpha #Radioligand #Therapies (#ART). Find out more about our unique approach at https://artbio.com/

#WilliamBlair #JefferiesHealthcare #RadioligandTherapy #Radiopharmaceuticals #Biotech #NuclearMedicine

 AlphaGen And ArtBio Form China-US Radioligand Partnership 


              New England Venture Capital Association Announces Nominees for the 12th Annual NEVY Awards
            

FogPharma, ARTBIO Partner to Develop Helicon-Enabled ARTs (HEARTs) - Contract Pharma

FogPharma, ARTBIO Partner To Develop Helicon-Enabled ARTs (HEARTs) - Contract Pharma

ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New York and Surrounding States - PR Newswire

Apply for this job

 SpectronRx and ARTBIO Join Forces to Develop and Manufacture Clinical Supply of Novel Alpha Radioligand Therapy ... 

 Rain in Gaza: Displaced Palestinians Face Heightened ... 

 ARTBIO and PharmaLogic Announce Supply Agreement for Lead-212 based Therapeutic Candidate AB001 for New ... 


                Breakthrough mini-protein revolutionizes how we treat cancer
              

Research & DevelopmentPrincipal Scientist/Associate Director, Peptide ChemistryCambridge, MA


              Emanuele Ostuni - CEO, ARTBIO
            

ARTBIO will attend the 4th annual ICPO Foundation-International Centers for Precision Oncology Forum in Garching, Germany, and our VP Clinical Development Vicki Jardine is presenting Pb212 clinical opportunities for targeted #alpha #radioligand #therapies.
 
Be sure to check out her session on May 16th at 15:30 CET.
 
#nuclearmedicine #biotech #radiopharmaceuticals #RadioligandTherapy #LifeSciences #CancerCare

Investors pour $90M onto ARTBIO's palette less than 6 months after launching - Fierce Biotech

Artbio raises $90M as radiopharma field finds its footing - Endpoints News

ARTBIO

Business:

Drug notes:

About: